Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results